PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

• Antonio Salar Silvestre,
• Judith Trotman,
• Clementine Sarkozy,
• Yuqin Song,
• Laurie H. Sehn,
• Loretta J. Nastoupil,
• Wanhua Zhang,
• Pierre Fustier,
• Richard Delarue,
• Pier Luigi Zinzani

Affiliations

Antonio Salar Silvestre

1 Hospital del Mar, Barcelona, Spain

Judith Trotman

2 Concord Repatriation General Hospital, University of Sydney, Concord, Australia

Clementine Sarkozy

3 Institut Curie, Paris, France

Yuqin Song

4 Peking University Cancer Hospital and Institute, Beijing, China

Laurie H. Sehn

5 University of British Columbia, Vancouver, Canada

Loretta J. Nastoupil

6 MD Anderson Cancer Center, Houston, United States

Wanhua Zhang

7 BeiGene USA, Inc., San Mateo, United States

Pierre Fustier

7 BeiGene USA, Inc., San Mateo, United States

Richard Delarue

7 BeiGene USA, Inc., San Mateo, United States

Pier Luigi Zinzani

8 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy